Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Questcor Pharmaceuticals Inc (QCOR), Avanir Pharmaceuticals, Inc. (AVNR): 3 Humongous Healthcare Stocks This Past Week

Page 1 of 2

Investors in a handful of health-care stocks are probably all smiles this week. Several stocks saw nice double-digit gains over the past five days. Here are three of the biggest winners.

Co-opting the competition

Questcor Pharmaceuticals Inc (NASDAQ:QCOR) ranks at the top of the list. Shares soared 27% on news that the company is acquiring a potential rival drug.

Earlier this week, Questcor Pharmaceuticals Inc (NASDAQ:QCOR) announced that it’s buying rights to Synacthen from Novartis AG (ADR) (NYSE:NVS) for $135 million plus potential milestone payments. Synacthen is a synthetic form of adrenocorticotropic hormone, or ACTH, and has been viewed as a potential threat to Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s Acthar gel. While Synacthen isn’t yet available in the U.S., the drug sells elsewhere in the world for only a fraction of Acthar’s cost.

Questcor Pharmaceuticals Inc (NASDAQ:QCOR)

Skeptics of Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s success have long maintained that the company would inevitably face competition from lower-cost alternative drugs. Questcor appears to have headed off one of those threats with this acquisition. The company says it plans to actively promote Synacthen for different indications than those for which Acthar is used and potentially some common indications where the synthetic product shows better clinical efficacy.

On a roll

Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) is on a roll. After solid gains during the first week of June, the stock jumped another 19% this week.

The primary source of investor excitement stems from a Food and Drug Administration decision announced last week to allow a faster development path for AVP-786, which is basically a newer version of Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR)’s Nuedexta. Avanir will now be able to use some data from Nuedexta studies in support of its Investigational New Drug, or IND, application process for AVP-786.

This week, Japanese investment firm Mizuho initiated coverage of Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) with a “buy” rating. Mizuho established a price target of $10 per share, more than double the stock’s current price.

Sell-off leads to buying?

Home health and hospice provider Amedisys Inc (NASDAQ:AMED) also had a great week. Shares climbed 14%.

What precipitated these nice gains? Amedisys made no major announcements other than to report results from its annual stockholder meeting held on June 6. There wasn’t anything in that announcement to fire up investors, though.

Piper Jaffray raised its price target on Amedisys Inc (NASDAQ:AMED). However, its new target is $12 per share — well below where the stock already trades.

Amedisys did announce in late May that it had retained a firm to sell around 35 care centers that aren’t performing as well as desired. This move could be behind some of the renewed interest in the stock.

Whatever is behind the latest demand driving up Amedisys shares, it’s certainly good news for those who have owned the stock for a while. Amedisys is currently trading at the highest levels since last October, when shares were in the midst of a slide that eventually wiped away nearly 40% of the company’s valuation.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!